Researchers analyzed data from 3,459 adults with obesity, including those with and without diabetes. They compared the effects of two different doses of a medication called orforglipron: a 12 mg dose and a 36 mg dose. The goal was to see how each dose affected weight, blood sugar, and other health markers.
The results showed that the 36 mg dose led to a significantly greater reduction in body weight and body mass index compared to the 12 mg dose. Additionally, the higher dose was linked to better reductions in HbA1c levels, waist circumference, triglycerides, and systolic blood pressure. These findings suggest that the higher dose may be more effective for managing weight and metabolic health.
In terms of safety, the study found that both doses had similar rates of gastrointestinal events and impacts on pancreatic function. While there was a small increase in certain liver enzymes with the 36 mg dose, it was not considered a major safety concern in this analysis. However, the study was not designed to detect rare or long-term side effects. These results are based on a meta-analysis, which combines data from multiple trials, but you should talk to your doctor about how these findings apply to your specific health needs.
